Should I Buy SRRK? SRRK 2026 Analysis

Should You Buy Scholar Rock Holding Corp (SRRK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

49.960

1 Day change

-0.08%

52 Week Range

51.620

Analysis Updated At

2026/04/17

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Scholar Rock Holding Corp (SRRK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, positive technical indicators, and significant potential for its lead drug apitegromab in spinal muscular atrophy make it a compelling investment opportunity despite the current pre-market dip.

Technical Analysis

The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 64.715, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its support level (S1: 48.086), providing a potential entry point.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The open interest put-call ratio of 1.03 suggests a balanced sentiment, while the option volume put-call ratio of 0.89 indicates slightly higher call volume, reflecting a mildly bullish sentiment.

Technical Summary

Sell

Buy

Positive Catalysts

Multiple analysts have raised price targets, with the highest at $70, and maintain strong Buy ratings.
The resubmission of the BLA for apitegromab with FDA alignment is seen as a de-risking event.
Scholar Rock's apitegromab is positioned to dominate the SMA market with multi-billion dollar potential.
The company has addressed prior manufacturing concerns with dual fill-finish partners, ensuring supply chain readiness.

Neutral/Negative Catalysts

The company is still in a pre-revenue phase, with no revenue growth in the latest quarter.
The pre-market price has dipped by 2.92%, which may indicate short-term selling pressure.

Financial Performance

In Q4 2025, the company reported a net income loss of $90.97M, which improved by 36.88% YoY. EPS also improved to -0.75, up 22.95% YoY. However, the company remains in a pre-revenue phase with no gross margin.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on SRRK, with multiple firms raising price targets and maintaining Buy or Strong Buy ratings. The consensus highlights the potential approval and commercial success of apitegromab, with expected multi-billion dollar sales and market dominance in SMA.

11 Analyst Rating

Wall Street analysts forecast SRRK stock price to rise

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 49.960

Low

Averages

High

Current: 49.960

Low

Averages

High

Canaccord

Buy

initiated

$62

AI Analysis

2026-04-20

New

Reason

Canaccord

Price Target

$62

AI Analysis

2026-04-20

New

initiated

Buy

Reason

Canaccord initiated coverage of Scholar Rock with a Buy rating and $62 price target.

Jefferies

Buy

maintain

$54 -> $57

2026-04-01

Reason

Jefferies

Price Target

$54 -> $57

2026-04-01

maintain

Buy

Reason

Jefferies raised the firm's price target on Scholar Rock (SRRK) to $57 from $54 and keeps a Buy rating on the shares. Scholar Rock resubmitted its apitegromab biologics license application with included both Novo (NVO)/Catalent and second fill/finish sites, the analyst tells investors in a research note. The firm said management noted that the decision to resubmit before reinspection was FDA-aligned and driven by progress across both sites; that second filler will have commercial supply as early as July, and; the company has the flexibility to drop either filler to streamline review and can hit its September date regardless of reinspection outcome.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRRK

Unlock Now

SRRK Should I Buy

SRRK Should I Buy

Should You Buy Scholar Rock Holding Corp (SRRK) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch